The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The comprehensive analysis of relationship between gut microbiome and treatment outcome of androgen deprivation therapy (ADT)-based treatment in patients with metastatic castration-sensitive and -resistant prostate cancer.
 
Nobuaki Matsubara
Honoraria - Sanofi
Consulting or Advisory Role - Amgen; AstraZeneca; Janssen; Lilly; Pfizer; Sanofi; Seagen
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer Yakuhin (Inst); Chugai Pharma (Inst); Eisai (Inst); Janssen (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Roche/Genentech (Inst); Seagen (Inst); Takeda (Inst)
 
Shunsuke Sakai
No Relationships to Disclose
 
Riu Yamashita
Consulting or Advisory Role - Takeda
 
Toshihiro Misumi
No Relationships to Disclose
 
Masaki Shiota
Honoraria - Astellas Pharma; AstraZeneca; Bayer Yakuhin; Chugai Pharma; Janssen; Sanofi; Takeda
Research Funding - Daiichi Sankyo/UCB Japan; Kubix
 
Masatoshi Eto
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Eisai; Merck; Pfizer; Takeda
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Eisai; Merck; MSD; Ono Pharmaceutical; Takeda
Research Funding - Ono Pharmaceutical; Sanofi; Takeda
 
Taigo Kato
Research Funding - Pfizer; Takeda
 
Takahiro Osawa
Honoraria - Takeda
 
Takashige Abe
No Relationships to Disclose
 
Nobuo Shinohara
Honoraria - AstraZeneca; Bayer; Janssen; MSD; Ono Pharmaceutical; Pfizer; Sanofi; Takeda
Research Funding - Bristol-Myers Squibb; Ono Pharmaceutical; Takeda
 
Koshiro Nishimoto
No Relationships to Disclose
 
Yota Yasumizu
No Relationships to Disclose
 
Nobuyuki Tanaka
No Relationships to Disclose
 
Mototsugu Oya
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Janssen; MSD; Novartis; Ono Pharmaceutical; Pfizer; Sanofi; Takeda
Consulting or Advisory Role - Bayer
Research Funding - Astellas Pharma
 
Takao Fujisawa
Honoraria - Merck Serono
 
Satoshi Horasawa
No Relationships to Disclose
 
Yoshiaki Nakamura
Honoraria - Chugai Pharma; Guardant Health AMEA; Merck
Research Funding - Chugai Pharma (Inst); Genomedia (Inst); Guardant Health (Inst); Guardant Health (Inst); Roche (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst)
 
Takayuki Yoshino
Honoraria - Bayer Yakuhin; Chugai Pharma; Merck; MSD K.K.; Ono Pharmaceutical
Research Funding - Amgen (Inst); Chugai Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); Genomedia (Inst); MSD (Inst); Nippon Boehringer Ingelheim (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst)
 
Norio Nonomura
Stock and Other Ownership Interests - Shionogi
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Janssen; Merck; MSD K.K; Novar Pharma; Ono Pharmaceutical; Pfizer; Takeda
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); J-Oil Mills (Inst); Nippon Shinyaku (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)